Colicin type 7 produced by majority of Shigella sonnei isolated from Thai patients with diarrhoea

Kaewklom, Siriporn; Samosornsuk, Seksun; Pipatsatitpong, Duangnate; Aunpad, Ratchaneewan

doi:10.1590/s1517-83822013000300010

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… S. sonnei possesses multiple antibacterial mechanisms. The majority of clinical isolates produce colicins ( 29 , 32 , 33 ), which are effective against a narrow phylogenetic range of bacteria. While S. flexneri cells are also reported to produce bacteriocins ( 34 ), there are few studies indicating the prevalence or identity of bacteriocins in S. flexneri clinical isolates.…”

Section: Discussionmentioning

confidence: 99%

Shigella sonnei Does Not Use Amoebae as Protective Hosts

Watson

Jenkins

Clements

2018

Appl Environ Microbiol

View full text Add to dashboard Cite

Shigella flexneri and Shigella sonnei bacteria cause the majority of all shigellosis cases worldwide. However, their distributions differ, with S. sonnei predominating in middle- and high-income countries and S. flexneri predominating in low-income countries. One proposed explanation for the continued range expansion of S. sonnei is that it can survive in amoebae, which could provide a protective environment for the bacteria. In this study, we demonstrate that while both S. sonnei and S. flexneri can survive coculture with the free-living amoebae Acanthamoebae castellanii, bacterial growth is predominantly extracellular. All isolates of Shigella were degraded following phagocytosis by A. castellanii, unlike those of Legionella pneumophila, which can replicate intracellularly. Our data suggest that S. sonnei is not able to use amoebae as a protective host to enhance environmental survival. Therefore, alternative explanations for S. sonnei emergence need to be considered.IMPORTANCE The distribution of Shigella species closely mirrors a country's socioeconomic conditions. With the transition of many populous nations from low- to middle-income countries, S. sonnei infections have emerged as a major public health issue. Understanding why S. sonnei infections are resistant to improvements in living conditions is key to developing methods to reduce exposure to this pathogen. We show that free-living amoebae are not likely to be environmental hosts of S. sonnei, as all Shigella strains tested were phagocytosed and degraded by amoebae. Therefore, alternative scenarios are required to explain the emergence and persistence of S. sonnei infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Shigella sonnei Does Not Use Amoebae as Protective Hosts

Watson

Jenkins

Clements

2018

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…Numerous bacteriocins produced by different members of the Shigella genus have been described (Calcuttawala et al 2015, Kaewklom et al 2013. All of these were classified as colicins.…”

Section: Introductionmentioning

confidence: 99%

Characterization of a bacteriocin produced by a clinical isolate of Shigella flexneri 2

Lamberti

López

Pescaretti

et al. 2022

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

This study was conducted to determine the emergence of antibiotic producer Shigella strains, focusing the efforts in the search of new antimicrobial compounds. The ability of 388 Shigella isolates, which were originated from 15,131 fecal samples from patients with acute diarrhea analyzed between 2015-2017, to produce antimicrobial peptides was determined by deferred-antagonism assay. Here, we observed that 9.02% of the Shigella isolates produced an antimicrobial agent able to inhibit the E. coli AB133 strain growth. The CI172 strain was selected as producer for its antimicrobial characterization. This antagonist compound (ShpCI172) was produced during exponential growth phase and displayed a restricted action spectrum. It is also thermo-resistant and has about 3 kDa molecular mass. The ShpCI172 can be classifi ed as a microcin, since CI172 did not display cross immunity with other well-known microcins. This is the fi rst report where the production of a microcin by a Shigella fl exneri 2 strains is described. The use of ShpCI172 microcin may contribute to preventing or controlling diarrheal diseases. This fi nding represents an important contribution in the biotechnology fi eld for its potential in the development of new antibiotics and/or food preservatives agents.

show abstract